Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Tongue Neoplasms 1Stomatitis 1Somatostatinoma 1Radiation Injuries 1Prostatic Neoplasms 1Paraganglioma 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Mouth Neoplasms 1Mediastinal Neoplasms 1Laryngeal Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gliosarcoma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Adenoma, Islet Cell 1

Interventions

Everolimus 8Temozolomide 7Sunitinib 6Specimen Handling 4Octreotide 4Magnetic Resonance Spectroscopy 4Fluorouracil 4Capecitabine 4lutetium Lu 177 dotatate 3Leucovorin 3sargramostim 2montanide ISA 51 2incomplete Freund's adjuvant 2cabozantinib 2Thalidomide 2Streptozocin 2Oxaliplatin 2Irinotecan 2Injections 2Doxorubicin 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1sapanisertib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1nimotuzumab 1napabucasin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenoma, Islet Cell × Salts × Clear all
NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 1 Completed
19 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡